Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 8/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL343600 | 0.91 | AURKA (0.39) | RBP4HCRTR1HCRTR2AURKAAURKB | |
| Trifluoroacetic Acid SCHEMBL343601 | 0.91 | AURKA (0.39) | RBP4HCRTR1HCRTR2AURKAAURKB | |
| SCHEMBL343491 | 0.90 | HCRTR1 (0.38) | RBP4HCRTR1HCRTR2ROCK2RET | |
| SCHEMBL343490 | 0.90 | HCRTR1 (0.38) | RBP4HCRTR1HCRTR2ROCK2RET | |
| SCHEMBL343492 | 0.90 | HCRTR1 (0.38) | RBP4HCRTR1HCRTR2ROCK2RET | |
| Trifluoroacetic Acid SCHEMBL343086 | 0.88 | AURKA (0.39) | RBP4HCRTR1HCRTR2AURKAAURKB | |
| Trifluoroacetic Acid SCHEMBL343084 | 0.88 | AURKA (0.39) | RBP4HCRTR1HCRTR2AURKAAURKB | |
| SCHEMBL342592 | 0.86 | KDM4E (0.45) | — | |
| SCHEMBL341449 | 0.86 | KDM4E (0.45) | — | |
| SCHEMBL341655 | 0.86 | RBP4 (0.35) | RBP4ROCK2PPARGSYKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367690-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | VERTEX PHARMACEUTICALS INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | RBP4 4608/4885HCRTR1 619/4885HCRTR2 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.